Navigation Links
YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS
Date:11/11/2009

pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in ongoing and future clinical trials; that AeroLEF(R) will continue to generate positive efficacy and safety data in future clinical trials; and that YM and its various partners will complete their respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

    Summary financial statements attached:

    YM BIOSCIENCES INC.
    Interim Consolidated Balance Sheets
    (Expressed in Canadian dollars,
     unless otherwise noted)

    -------------------------------------------------------------------------
                                                September 30,        June 30,
                                                        2009            2009
    -------------------------------------------------------------------------
                                                  (Unaudited)

    Assets

    Current assets:
      Cash                                     $  34,269,093   $   2,337,716
      Short-term deposits                          5,205,955      39,713,042
      Accounts receivable                            439,911         564,584
      Prepaid expenses                               231,488         352,850
      -----------------------------------------------------------------------
                                                  40,146,447      42,968,192

    Property and equipment                            84,187          96,876

    Intangible assets                             
'/>"/>
SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... SUNNYVALE, Calif. , Feb. 27, 2015 /PRNewswire/ ... announced that longer-term toxicology studies for its newly ... arthritis, or RA, have been completed. The results ... the U.S. Food and Drug Administration. The feedback ... completion of the ongoing first-in-human study. Additional preclinical ...
(Date:2/27/2015)... Halifax, Nova Scotia (PRWEB) February 27, 2015 ... clinical stage vaccine and immunotherapy company, today announced ... approved its application for Fast Track designation and ... DPX-Ebola vaccines, in conjunction with the mutual co-development ... had previously obtained Fast Track designation for the ...
(Date:2/27/2015)... Feb. 27, 2015  Pfenex Inc. (NYSE MKT: PFNX), ... biosimilar therapeutics, today announced that it will be presenting ... on March 2 nd at 3pm PST. Patrick Lucy, ... panel discussing the current state of the biosimilar industry ... For more information on CALBIO 2015 ...
(Date:2/27/2015)... 2015  Steep Hill, the industry leader in cannabis ... to open a full service medical cannabis quality assurance ... bringing advanced scientific tools and methodology to the state, ... is currently the only laboratory licensed by the New ... testing in order to meet the recently adopted regulatory ...
Breaking Biology Technology:Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3Steep Hill First to Receive Provisional Approval to Establish Laboratory Services for Cannabis Testing in State of New Mexico 2
... , , WEST CHESTER and ... a leading global medical device company in the orthopaedic trauma, spine, ... (Nasdaq: KNSY ), a leading developer and manufacturer of ... developed from Kensey Nash,s unique extracellular matrix (ECM) technology. , ...
... Ltd,(SIX: ARPN) announced today its financial results for the six months ending,30 ... - Regulatory setback for intravenous iclaprim in cSSSI in ... - Company restructuring completed, , Cash and financial ... CFO Harry Welten, MBA, commented: "Our cost-saving measures have been,implemented, ...
... , , CLEVELAND, Aug. 19 It,s ... field using technology in a "meaningful" way. While it,s clear ... the exact role technology will play to help achieve that goal. Proven ... or administrative, at the right time, content management will clearly play an ...
Cached Biology Technology:Synthes and Kensey Nash Announce Strategic Agreement for Extracellular Matrix Products 2Synthes and Kensey Nash Announce Strategic Agreement for Extracellular Matrix Products 3Synthes and Kensey Nash Announce Strategic Agreement for Extracellular Matrix Products 4Synthes and Kensey Nash Announce Strategic Agreement for Extracellular Matrix Products 5Arpida Reports Interim Results For Six Months to 30 June 2009 2Healthcare Continues to Use OnBase in 'Meaningful' Ways 2Healthcare Continues to Use OnBase in 'Meaningful' Ways 3Healthcare Continues to Use OnBase in 'Meaningful' Ways 4
(Date:2/5/2015)... 5, 2015  Marken is starting its 35 th ... launched a new marketing campaign to solidify its place ... new campaign focuses on First as a ... The first headline in the series, ... with its client,s priorities. Marken recognizes the need to ...
(Date:2/5/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD and ... focused on the growing mobile commerce market, announces it ... Conference on January 29 th at 10:30 a.m. ... of NXT-ID will present and host a live Q&A ... and its full suite of biometric technologies. Investors can ...
(Date:1/22/2015)... , Jan. 9, 2015 Valid S.A. ("Company") (BM&FBOVESPA: ... market in general the State of Washington,s ... for a new enrollment and central issuance system for driver,s ... The project planning and development will start in ...
Breaking Biology News(10 mins):Marken Launches New Patient-Centric Campaign 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3Valid USA Signs Contract For Washington Driver's License Issuance 2
... have all but disappearedwere home to dozens of species of ... hundreds of species of flowers, and herds of roaming bison. ... by the University of Colorado Boulder has gotten a peek ... once called the tallgrass prairie home: the diverse assortment of ...
... AMHERST, Mass. Usually indigestion is a bad thing, ... Robert Vass at the University of Massachusetts Amherst recently ... partial degradation of a DNA replication protein is required ... one of the most highly controlled biological processes in ...
... Institute of Biotechnology have used the power of ... atomic movements. The research is helping to chart ... "glycomes" - the entire complement of carbohydrates within ... new understanding of these vital biomolecules which play ...
Cached Biology News:CU-Boulder-led team gets first look at diverse life below rare tallgrass prairies 2Biochemists find incomplete protein digestion is a useful thing for some bacteria 2Gaming technology unravels 1 of the most complex entities in nature 2Gaming technology unravels 1 of the most complex entities in nature 3
... your microarray data using Asuragens bioinformatics ... need from consultation to extensive data ... date methods. Utilize our expertise in ... Service or from your own microarray ...
... This CLS number is a new ... Cornings product number. If showing no ... old Sigma-Aldrich number (Z71,517-4) or contact ... cap polystyrene (expanded surface, easy grip) ...
... number is a new product ... Cornings product number. If showing ... under the old Sigma-Aldrich number ... for assistance. Material: cap ...
... is a new product number, ... product number. If showing no ... the old Sigma-Aldrich number (Z71,704-5) ... assistance. ...
Biology Products: